ライフサイエンスコーパス: oxandrolone

1 the expression of 21 genes was altered with oxandrolone.

2 s determined before and after treatment with oxandrolone.

3 No serious adverse events were related to oxandrolone.

4 n care plus oxandrolone for at least 7 days (oxandrolone 0.1 mg/kg body weight q.12 hours p.o, n = 45

5 uary 1, 2001, and June 15, 2003, 18 received oxandrolone (10 mg po BID) and 23 received a placebo.

6 Oxandrolone, 20 mg/d (n = 108), or placebo (n = 104) unt

7 ndomization was between an anabolic steroid, oxandrolone, 20 mg/d, and placebo.

8 se drugs, and the combined administration of oxandrolone and propranolol at the same doses, for 1 yea

9 Combined administration of oxandrolone and propranolol attenuates burn-induced grow

10 mined whether the combined administration of oxandrolone and propranolol has added benefit.

11 Combined use of oxandrolone and propranolol shortened the period of grow

12 eutic roles of growth hormone, testosterone, oxandrolone, and megestrol acetate and emerging data on

13 d use of the synthetic testosterone analogue oxandrolone are the most cost effective and least toxic

14 Oxandrolone attenuates body catabolism during the acute

15 Oxandrolone did not adversely affect the endocrine and i

16 control, n = 190) or standard burn care plus oxandrolone for at least 7 days (oxandrolone 0.1 mg/kg b

17 mol/L (9.8 [5.4] mg/dL) significantly in the oxandrolone group (P < .001 compared with placebo).

18 ression changes were seen in 14 genes in the oxandrolone group compared to placebo.

19 One subject in the oxandrolone group discontinued the study because of elev

20 The oxandrolone group received higher caloric and protein in

21 (SD) gains were significantly greater in the oxandrolone group than in the placebo group (5.6 [2.1] v

22 The improvement in the oxandrolone group was associated with increased protein

23 ce decreased in controls and improved in the oxandrolone group.

24 Patients receiving oxandrolone had a longer intensive care unit stay but no

25 ilator-dependent surgical patients receiving oxandrolone had a more prolonged course of mechanical ve

26 Oxandrolone improved body composition and strength in se

27 Oxandrolone improved lean body mass, bone mineral conten

28 he administration of the testosterone analog oxandrolone improves lean body mass accretion and bone m

29 In burn victims, oxandrolone improves muscle protein metabolism through e

30 Oxandrolone improves protein net balance and lean mass i

31 These findings suggest the efficacy of oxandrolone in impeding muscle protein catabolism in cac

32 To study the efficacy of oxandrolone in severely burned children for 12 months af

33 The authors previously showed that oxandrolone increased net muscle protein synthesis in em

34 Oxandrolone is an anabolic steroid that attenuates loss

35 Oxandrolone is an anabolic steroid that has been used in

36 e of mechanical ventilation, suggesting that oxandrolone may be detrimental in this circumstance.

37 Oxandrolone may enhance collagen deposition and fibrosis

38 treatment with placebo (n = 18) or 0.1 mg/kg oxandrolone (n = 14) twice a day was started.

39 tients were randomized into those to receive oxandrolone (n = 30) or placebo (n = 31) for the first 1

40 The effects of oxandrolone on clinical outcome, body composition, endoc

41 The beneficial effects of oxandrolone on height and weight were observed 1 year af

42 , recombinant human growth hormone, insulin, oxandrolone, or anticatabolic drugs such as propranolol

43 week follow-up, 16.7% (CI, 9.6% to 23.7%) of oxandrolone recipients and 15.4% (CI, 8.5% to 22.3%) of

44 re elevated in 32.4% (CI, 23.6% to 41.2%) of oxandrolone recipients and 2.9% (CI, 0.0% to 6.1%) of pl

45 24.1% (95% CI, 16.0% to 32.1%) of TPUs in oxandrolone recipients and 29.8% (CI, 21.0% to 38.6%) in

46 ble-blinded, randomized single-center study, oxandrolone shortened length of acute hospital stay, mai

47 Oxandrolone showed no benefit over placebo for improving

48 to children for 1 year after a severe burn, oxandrolone significantly improves lean body mass, bone

49 Oxandrolone significantly increased serum prealbumin, to

50 ntrary to our hypothesis, patients receiving oxandrolone spent significantly longer time on the venti

51 iopsies were taken 1 week after treatment in oxandrolone subjects to examine gene expression changes

52 Control and oxandrolone subjects were similar in age, weight, and pe

53 n regimen that included an anabolic steroid, oxandrolone, substantially increased the lean tissue acc

54 d, double-blind, placebo-controlled trial of oxandrolone therapy for surgical/trauma patients requiri

55 are unit stay was significantly decreased in oxandrolone-treated patients (0.48 +/- 0.02 days/% burn)

56 /- 1% of their lean body mass (LBM), whereas oxandrolone-treated patients had preserved LBM (+9 +/- 4

57 e did not change in the placebo group, while oxandrolone-treated subjects had a significant improveme

58 bo group, while no changes were found in the oxandrolone-treated subjects.

59 s after admission, and again after 1 week of oxandrolone treatment at 0.1 mg/kg by mouth twice daily

60 Muscle net protein balance increased with oxandrolone treatment compared to placebo.

61 Postburn long-term oxandrolone treatment improves hypermetabolism and body

62 Children who received 0.1 mg/kg oxandrolone twice a day (n = 7) were compared to placebo

63 nificant increases in height and weight with oxandrolone were observed after the end of treatment.

64 It is unclear whether oxandrolone would have any beneficial effects during lon

65 We hypothesized that oxandrolone would improve outcome for ventilator-depende